Background Accurate evaluation of human being epidermal growth factor receptor type-2 (HER2) status based on core needle biopsy (CNB) specimens is mandatory Hydroxyflutamide (Hydroxyniphtholide) for identification of patients with primary breast cancer who will benefit from primary systemic therapy with trastuzumab. sections were subjected to HER2 testing by immunohistochemistry (IHC) and 27 paired sections were… Continue reading Background Accurate evaluation of human being epidermal growth factor receptor type-2